Pharma BD Deal Intelligence
A failed bet: Hospira's ~$400M purchase of Orchid's Chennai generic-injectables plant became a chronic FDA quality nightmare, hitting Import Alert and a 2013 warning letter, and after Pfizer acquired Hospira in 2015, Pfizer permanently shut the site in 2019 over falsified test records.
The acquired Chennai injectables plant became a chronic quality/data-integrity liability and was permanently shut down by Pfizer in 2019 — the ~$400M asset ended in closure, not cash flow.
Full analysis, sources & comparables →The Orchid deal adds a dedicated cephalosporin/penicillin/carbapenem complex and an Indian R&D base, positioning Hospira as a global low-cost injectables…
Post-deal, Orchid used the Hospira proceeds to pay down debt and refocus on APIs and non-beta-lactam formulations, validating the divestiture's strategic logic.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Hospira acquired Orchid Chemicals & Pharmaceuticals' generic injectables (beta-lactam) business and Indian manufacturing/R&D facility for ~$400M cash (closed Mar 30, 2010). Remove the 'Source:' clause.
The acquired Chennai injectables plant became a chronic quality/data-integrity liability and was permanently shut down by Pfizer in 2019 — the ~$400M asset ended in closure, not cash flow.
Assessment window: 15yr post-close.
Beta-lactam antibiotics (penicillins, cephalosporins, and carbapenems) are foundational sterile-injectable anti-infectives used in hospital and ICU settings for serious bacterial infections. The category is high-volume, low-margin, and supply-constrained because beta-lactams must be manufactured in dedicated, contained facilities to avoid cross-contamination.
By 2009 the global generic injectables market was consolidating around a small set of vertically integrated specialists: Hospira (the spinout from Abbott), Teva, Sandoz (Novartis), Sagent, APP Pharmaceuticals (Fresenius Kabi), and Indian players such as Dr. Reddy's, Sun Pharma, and Orchid itself. Orchid Chemicals & Pharmaceuticals' generic injectables unit was one of the top-five global generic beta-lactam antibiotics manufacturers, with a dedicated cephalosporin / penicillin / carbapenem complex plus an R&D facility at Irungattukottai near Chennai, and a portfolio of marketed sterile-injectable products and ANDA pipeline (Contract Pharma, Dec 2009; FierceBiotech, Dec 2009). For Hospira, the ~$400M cash deal added a low-cost India manufacturing base, a captive beta-lactam capability that complemented its existing Rocky Mount and Kansas plants, and an immediate ANDA pipeline at a moment when US hospitals were facing chronic injectable shortages. The deal closed March 30, 2010 and effectively shifted Hospira from a US-centric injectables player to a global one, foreshadowing Pfizer's 2015 acquisition of Hospira itself for ~$17B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) (this deal) | 2009 | $400M | 22 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
| Hospira Inc. / Javelin Pharmaceuticals, Inc. | 2010 | $145M | 25 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) | 2010 | $400M | 23 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) | 2012 | $200M | 22 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2009 deals · Hospira Inc. deals